Abbott (ABT) gains as 'strong' performance tops Q3 expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Abbott (ABT) Tops Q3 EPS by 4c, Raises Guidance
October 18, 2023 7:33 AM EDT(Updated - October 18, 2023 7:35 AM EDT)
Abbott (NYSE: ABT) reported Q3 EPS of $1.14, $0.04 better than the analyst estimate of $1.10 Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $9.82 billion.
GUIDANCE:
Abbott sees FY2023 EPS of $4.42-$4.46, versus... More
Abbott says market overestimating sales hit from new diabetes drugs
October 18, 2023 7:32 AM EDTBy Leroy Leo and Pratik Jain
(Reuters) - Abbott Laboratories said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the treatments could end up boosting sales of the medical device maker.
The company's shares have dropped 16% this year, mainly on concerns that new GLP-1 diabetes drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro could eat into the sales of its continuous glucose... More
Abbott Labs (ABT) PT Lowered to $105 at Mizuho Securities
October 17, 2023 6:41 AM EDTMizuho Securities analyst Anthony Petrone lowered the price target on Abbott Labs (NYSE: ABT) to $105.00 (from $115.00) while maintaining a Neutral rating.... More
Abbott Labs (ABT) PT Lowered to $118 at UBS
October 16, 2023 8:54 AM EDTUBS analyst Danielle Antalffy lowered the price target on Abbott Labs (NYSE: ABT) to $118.00 (from $130.00) while maintaining a Buy rating.... More
